Ir. G.J. Smidfonds has joined Pharma Connect Capital as a shareholder. The Smid foundation has a mission to support innovative industrial developments, in order to promote and improve business activities and employment in the Northern Netherlands. Management and current shareholders of Pharma Connect Capital very much welcome the support and participation of Smid Fonds, which has increased the total available capital of Pharma Connect Capital to € 8.5 million.

More info: G.J. Smidfonds 

← Unique Northern approach to developing new drugs February 2019: Pharma Connect Capital invests in BiOrion. →